Prevalence of Estrogen Receptor Variant Messenger RNAs in Human Breast Cancer
Overview
Authors
Affiliations
A new approach, based on the competitive amplification of wild-type and exon-deleted estrogen receptor (ER) variant cDNAs, was used to screen 100 human breast tumors for the presence of ER variants. Already described exon 4-deleted ER mRNA was preferentially detected in tumors with lower grades (P < 0.05) or higher progesterone receptor levels (P < 0.01), whereas new ER variants, deleted in exons 2-4 or in regions within exons 3-7 were associated with higher grades (P < 0.025) and higher ERs (P < 0.001). This approach allows investigation of the expression of multiple ER variant mRNAs and may implicate them as new prognostic markers and as possible contributors to tumor progression.
Anamthathmakula P, Kyathanahalli C, Ingles J, Hassan S, Condon J, Jeyasuria P EBioMedicine. 2018; 39:520-530.
PMID: 30502052 PMC: 6355643. DOI: 10.1016/j.ebiom.2018.11.038.
The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors.
Gu Y, Chen T, Lopez E, Wu W, Wang X, Cao J J Transl Med. 2014; 12:16.
PMID: 24447535 PMC: 3899443. DOI: 10.1186/1479-5876-12-16.
Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator.
Ohshiro K, Mudvari P, Meng Q, Rayala S, Sahin A, Fuqua S Mol Endocrinol. 2010; 24(5):914-22.
PMID: 20304996 PMC: 2870933. DOI: 10.1210/me.2009-0413.
Zheng Y, Zhang J, Xu Z, Sheng J, Zhang X, Wang H J Zhejiang Univ Sci B. 2010; 11(2):144-50.
PMID: 20104649 PMC: 2816318. DOI: 10.1631/jzus.B0900266.
Hopp T, Fuqua S J Mammary Gland Biol Neoplasia. 2000; 3(1):73-83.
PMID: 10819506 DOI: 10.1023/a:1018726418931.